Janssen Pharmaceuticals, Inc.
Recent News About Janssen Pharmaceuticals, Inc.
-
Companies have ammo if they want to make Utah opioid lawsuits cheaper to defend
SALT LAKE CITY (Legal Newsline) – Companies facing opioid litigation in Utah should be encouraged by a recent state Supreme Court decision that allowed the transfer of one of the cases – a sign that defendants might not have to fight more than 10 fronts in the state. -
Jurors won't get confused during huge opioid trial, judge rules; He'll set penalties after
CLEVELAND (Legal Newsline) – A jury will determine who, if anyone, is liable for the nation’s addiction crisis, but the judge overseeing a historic trial will decide how much they would pay. -
Oklahoma judge feeds the 'monster' with $572M opioid ruling against Johnson & Johnson
Sixteen years ago in a case involving gunmaker Sturm, Ruger & Co., a New York appeals court refused to apply public nuisance law against the manufacturer of a legal product, saying that doing so would transform nuisance law “into a monster that would devour in one gulp the entire law of tort.” -
Private lawyers stand to make $90 million as judge hits Johnson & Johnson with $572M opioid ruling
NORMAN, Okla. (Legal Newsline) - A state judge in Oklahoma has blamed Johnson & Johnson for the state's opioid crisis and ordered it to pay $572 million in damages, extending public nuisance law beyond its traditional boundaries into what may become an all-purpose tool for government lawsuits against product manufacturers. -
Janssen win in Philly Risperdal case overturned by appeals court
HARRISBURG – The Superior Court of Pennsylvania has reinstated a Risperdal lawsuit which was thrown out after 11 days of trial proceedings in a Philadelphia court in December 2016 and said its original granting of nonsuit was improper. -
Oklahoma's hired lawyers fight J&J's request to strike testimony; Witness was called a de facto member of State's legal team
NORMAN, Okla. (Legal Newsline) – Attorneys hired by the State of Oklahoma on July 1 filed a motion asking a judge to deny a request by lawyers for Johnson & Johnson to strike the testimony of a key state’s witness in a trial accusing J&J of creating an opioid epidemic. -
J&J's attempt to cut off Oklahoma's opioid lawsuit rejected by judge overseeing trial
NORMAN, Okla. (Legal Newsline) – Attorneys for Johnson & Johnson on Monday lost a bid to dismiss a lawsuit brought by contingency-fee lawyers hired by the State of Oklahoma who accused the company of creating an opioid epidemic. -
Doctor testifying for J&J won’t use the E-word in Oklahoma opioid trial
NORMAN, Okla. (Legal Newsline) – An Oklahoma doctor appearing as a witness for Johnson & Johnson on Wednesday under questioning by state attorneys refused to use the word “epidemic” to describe the state’s opioid crisis, but conceded opioid overdose deaths had gone up in recent years. -
Janssen says addicts would have struggled to snort its opioids; Nucynta broke coffee grinder during testing
NORMAN, Okla. (Legal Newsline) – A former researcher with Janssen Pharmaceuticals, the drug subsidiary of Johnson & Johnson, on Friday said the company’s opioid products were safe if used properly, while attorneys hired by Oklahoma alleged J&J had played loose with the facts. -
Oklahoma's AG is twisting the law to suit his high-profile opioid case, Johnson & Johnson says
NORMAN, Okla. (Legal Newsline) – Oklahoma’s attorney general and the private lawyers he hired – who are earning millions from a lawsuit over the nation’s addiction crisis – are using a mangled interpretation of state law as they seek to generate headlines, one of the sued companies says. -
'A tipping point:' Punitive damages question to be decided in pair of Philadelphia Risperdal cases
PHILADELPHIA – A Philadelphia judge’s decree has paved the way for new trials in two Risperdal cases, in order to determine the applicability of punitive damages in those same actions. -
In Philadelphia, only 16% of new pharma cases are from Pennsylvania residents
PHILADELPHIA – A notable 2017 U.S. Supreme Court decision intended to limit the practice of forum-shopping has not deterred thousands of plaintiffs from filing pharmaceutical litigation in Philadelphia courts, recently-released statistics show. -
Unbeaten at trial, Bayer and Janssen say cycle of Xarelto lawsuits 'needs to be stopped'
Early returns haven't been positive for plaintiffs attorneys, so Xarelto liability theories have been mutating, defense says